Show simple item record

dc.contributor.authorPatel, NSA
dc.contributor.authorNandra, KK
dc.contributor.authorThiemermann, C
dc.date.accessioned2012-10-19T16:24:57Z
dc.date.issued2012-07-26
dc.date.issued2012
dc.date.issued2012-07-26
dc.date.issued2012-07-26
dc.date.issued2012-07-26
dc.date.issued2012-07-26
dc.identifier.urihttp://qmro.qmul.ac.uk/jspui/handle/123456789/2828
dc.descriptionAuthor can archive publisher's pdf. Free via Creative Commons: CC-BENCHTOBEDSIDE-2.0. © 2012 BioMed Central Ltd.en_US
dc.description.abstractErythropoietin (EPO) is known to have numerous biological functions. Its primary function in the body is to increase red blood cell numbers by way of preventing the apoptosis of erythroid progenitor cells via the homodimeric EPO receptor. The discovery that the local production of EPO within the brain in response to hypoxia or ischemia protects neurons against injury via an anti-apoptotic effect formed the basis of the hypothesis that the local generation of EPO limits the extent of injury. Although the hypothesis proved to be true in pre-clinical models of ischemia/reperfusion injury and inflammation, the randomized, controlled clinical trials that followed demonstrated serious adverse events of EPO due to activation of the hematopoietic system. Consequently, derivatives of EPO that lacked erythropoietic activity were discovered to reduce injury in many pre-clinical models associated with ischemia and inflammation. Unfortunately, there are no published clinical trials to determine the efficacy of non-erythropoietic derivatives of EPO in humans.
dc.format.extent229 - ?
dc.languageeng
dc.language.isoenen_US
dc.relation.ispartofCrit Care
dc.subjectCritical Care
dc.subjectErythropoietin
dc.subjectHumans
dc.titleBench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care.
dc.typeJournal Article
dc.identifier.doi10.1186/cc11315
dc.relation.isPartOfCrit Care
dc.relation.isPartOfCrit Care
dc.relation.isPartOfCrit Care
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/22839413
pubs.issue4
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/William Harvey Research Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/William Harvey Research Institute/Experimental Medicine & Rheumatology
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/William Harvey Research Institute/REF William Harvey Research Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/William Harvey Research Institute/Translational Medicine & Therapeutics
pubs.publication-statusPublished online
pubs.volume16


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Return to top